Novel nucleases with diverse properties represent promising solutions, emphasizing their potential to overcome current limitations in genome editing and therapeutic delivery.
Giedrius Gasiūnas
Advertisement
Giedrius Gasiūnas, PhD, is chief scientific officer at Caszyme.
Articles by Giedrius Gasiūnas
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Everything to Know About Cell and Gene Therapy in 2025
2
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
5
